ARTICLE | Company News

Eli Lilly, Isis extend antisense deal

August 9, 2005 12:43 AM UTC

LLY and ISIS extended a 2001 research deal. The partners extended the four-year deal for two more years, and LLY licensed from ISIS a third antisense compound to treat cancer: ISIS 345794, a second-ge...